| DC70530 |
JTP-0157602 |
JTP-0157602 (JTP0157602) is a novel non-catalytic site integrase inhibitor of HIV-1 integrase (IN), inhibits the interaction between LEDGF IBD and IN with IC50 of 4.2 nM.JTP-0157602 exhibits potent antiviral activity against HIV-1 with EC90 of 138 nM.JTP-0157602 retained potent antiviral activity (EC50=1-6 nM) against a broad panel of recombinant viruses with INSTI-related resistant mutations, including multiple substitutions that emerged in clinical studies of INSTIs (IN strand transfer inhibitors (INSTIs).JTP-0157602 inhibited HIV-1 replication mainly during the late-phase of the replication cycle.JTP-0157602 binds to the LEDGF/p75 binding pocket of HIV-1 integrase (IN). |
|
| DC70543 |
KNI-1657 |
KNI-1657 (KNI1657) is a highly potent HIV-1 protease inhibitor (97% inhibition at 1 nM) with high sensitivity against lopinavir/ritonavir- or darunavir-resistant strains; inhibits wild-type HIV-1 (pNL4-3) and LPV-resistant strain A17 with IC50 of <3 and 25 nM, respectively. |
|
| DC70640 |
NBD-14273 |
NBD-14273 is a CD4-mimetic, small-molecule HIV-1 entry inhibitor with IC50 of 0.13 uM.NBD-14273 showed both improved antiviral activity and selectivity index (SI) against HIV-1HXB2 compared to NBD-14136.NBD-14273 displayed potenct against a large panel of 50 HIV-1 Env-pseudotyped viruses representing clinical isolates of diverse subtypes. |
|
| DC70722 |
Q308
Featured
|
Q308 is a small molecule that silences the latent HIV-1 provirus by inhibiting Tat-mediated gene transcription and selectively downregulates the expression levels of the facilitated chromatin transcription (FACT) complex.Q308 induced the preferential apoptosis in HIV-1 latently infected cells, Q308 may reduce the size of the viral reservoir. |
|
| DC70753 |
S2C3 |
S2C3 is a small molecule HIV-1 fusion inhibitor, targets the membrane proximal external region (MPER) of HIV-1 envelope spike.S2C3 interacted with gp41-inter with an affinity of 2.0 uM.S2C3 has been shown to effectively block binding to the intact HIV-1 Env expressed on the cell surface by soluble CD4 but not by CD4 binding the sitedirected NAb VRC01, or the prefusion conformation-specific NAb PG16.S2C3 targets a site in the HIV-1 Env distinct from sites targeted by small-molecule entry inhibitors that have been identified so far.S2C3 could stabilize HIV-1 Env in the prefusion conformation, making it potentially useful in a vaccine preparation to reduce the conformational flexibility of Env. |
|
| DC70756 |
SBI-0637142 |
SBI-0637142 is a potent Smac mimetic that preferentially targets BIRC2, latency-reversing agent (LRA), specifically and potently promote HIV-1 latency reversal activity.SBI-0637142 modestly induced HIV-1 latency ex vivo in CD4+ T cells from ART-suppressed aviremic HIV-infected patients as a single agent, showed robust activity when administered in combination with the HDACi panobinostat.SBI-0637142's latency reversal activity is dependent on the NIK-dependent NF-κB signaling. |
|
| DC70797 |
SRI-41897 |
SRI-41897 is a specific small molecule inhibitor of HIV-1 N-terminal region of NL4-3 Vpu (HIV-1 NL4-3 Vpu) with EC50 of 4.4 uM in the GaLV inhibition assays.SRI-41897 blocks Vpu-mediated modulation of CD4, BST-2/Tetherin and antibody dependent cell-mediated toxicity (ADCC).SRI-41897 rescues CD4 surface expression by 47% on infected TZM-GFP cells, also rescues the expression of CD4 and Tetherin in human peripheral blood mononuclear cells (PBMCs). |
|
| DC71138 |
AL-470 |
AL-470 is a potent antiviral agent with EC50 values of 0.27, 0.63, and 0.35 µM against HIV-1, HIV-2, and EV-A71, respectively. |
|
| DC71276 |
WRNA10 |
WRNA10 is a potent HIV-1 TAR RNA binder with an IC50 of 10 µM and an CC50 of 40 µM. |
|
| DC71277 |
CI-39 |
CI-39 is an antiviral natural product. CI-39 is an NNRTI (non-nucleoside reverse transcriptase inhibit) antiviral agent with an EC50 of 3.40 µM and an CC50 of >30 µM for wild type HIV-1. CI-39 inhibits HIV-1 RT DNA polymerase and ribonuclease H activitiessup. |
|
| DC71278 |
A3N19 |
A3N19 is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor, with an EC50 of 3.28 nM against HIV-1 IIIB. |
|
| DC71482 |
RPR103611 |
RPR103611, the betulinic acid derivative, is a potent HIV-1 entry inhibitor with IC50s of 80, 0.27, and 0.17 for CCR5-tropic virus YU2, CXCR4-tropic virus NL4-3 and dual tropic virus 89.6, respectively. |
|
| DC71483 |
WAY-383487 |
WAY-383487 is one of the Tat peptide derivatives and inhibits HIV-1 long terminal repeat-activated transcription. |
|
| DC71675 |
Raltegravir sodium |
Raltegravir (MK 0518) sodium is a potent and orally active integrase (IN) inhibitor, used to treat HIV infection. |
|
| DC71712 |
EP39 |
EP39 is a potent HIV-1 maturation inhibitor. EP39 interacts with the SP1 domain of Gag. EP39 decreases the dynamics of CA-SP1 junction, by binding to the QVT motif of the SP1 domain, and perturbs the natural coil-helix equilibrium on both sides of the SP1 domain by stabilizing the transient alpha helical structure. EP39 acts by arresting maturation of HIV-1 thereby blocking its infectivity. |
|
| DC71713 |
ZLM-66 |
ZLM-66 is an orally active non-nucleoside reverse transcriptase inhibitors (NNRTIs) and biphenyl-containing doravirine analog. ZLM-66 shows an EC50 value of 13 nM against wild-type HIV-1. ZLM-66 can be used for the research of HIV. |
|
| DC72011 |
Abacavir hydrochloride |
Abacavir hydrochloride is a competitive, orally active nucleoside reverse transcriptase inhibitor. Abacavir hydrochloride can inhibits the replication of HIV. Abacavir hydrochloride shows anticancer activity in prostate cancer cell lines. Abacavir hydrochloride can trespass the blood-brain-barrier and suppresses telomerase activity. |
|
| DC72153 |
L-Fd4A |
L-Fd4A is an adenine derivative. L-Fd4A has anti-human immunodeficiency virus (HIV) (EC50=1.5 μM) and anti-hepatitis B virus (HBV) (EC50=1.7 μM) activity. L-Fd4A has low cytotoxicity. |
|
| DC72154 |
BI-2540 |
BI-2540 is a HIV non-nucleoside reverse transcriptase (NNRT) inhibitor. |
|
| DC72155 |
L-2'-Fd4C |
L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity. |
|
| DC72263 |
SKF107457 |
SKF107457 is an HIV-1 protease inhibitor that can be used in AIDS research. |
|
| DC72292 |
JE-2147 |
JE-2147 (AG1776) is a potent dipeptide protease inhibitor with a Ki of 0.33 nM for HIV-1 protease. JE-2147 has effective activities against a wide spectrum of HIV-1, HIV-2, simian immunodeficiency virus, and various clinical HIV-1 strains in vitro. |
|
| DC72578 |
AZT triphosphate tetraammonium |
AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) tetraammonium is an active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate tetraammonium exhibits antiretroviral activity and inhibits replication of HIV. AZT triphosphate tetraammonium also inhibits the DNA polymerase of HBV. AZT triphosphate tetraammonium activates the mitochondria-mediated apoptosis pathway. |
|
| DC72579 |
Carbovir triphosphate |
Carbovir triphosphate (CBV-TP) is a phosphorylated metabolite. Carbovir triphosphate can be used for the research of human immunodeficiency virus (HIV). |
|
| DC72780 |
R-87366 |
R-87366 is a water-soluble human immunodeficiency virus (HIV) protease inhibitor. R-87366 has potent inhibitory for HIV protease with a Ki value of 11 nM. R-87366 can be used for the research of anti-human immunodeficiency virus (HIV). |
|
| DC72879 |
TBA-7371 |
TBA-7371 (TBA7371, AZ 7371) is a potent, non-covalent inhibitor of decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) with IC50 of 10 nM, an enzyme involved in mycobacterial cell wall biogenesis. |
|
| DC72984 |
GS-9770 |
GS-9770 is a potent, selective, non-peptidomimetic and orally active HIV protease inhibitor with Ki(app) value of 0.16 nM (recombinant HIV-1 PR). |
|
| DC72985 |
GSK3839919 |
GSK3839919 is a potent, allosteric HIV-1 integrase inhibitor (ALLINI). |
|
| DC72986 |
GSK878 |
GSK-878 (GSK878) is a highly potent, long-acting inhibitor targeting the HIV-1 capsid with picomolar potency against HIV-1 infection in vitro (EC50=39 pM). |
|
| DC72987 |
iPAF1C |
iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal. |
|
